{ "generated": "2026-08-13T21:35:25.115Z", "conditions": { "osteoarthritis": { "name": "Osteoarthritis and chronic joint pain", "short": "Degenerative joint disease, the most common source of chronic pain in older dogs.", "description": "Osteoarthritis affects a large share of dogs over eight, and often shows up as reluctance on stairs, slowness to rise, or shortened walks rather than obvious limping. It is the best-studied condition in canine geriatric medicine, which means owners here have real randomized evidence to work from.", "measured_by": "Owner-reported instruments (Canine Brief Pain Inventory, Liverpool Osteoarthritis in Dogs, Canine Orthopaedic Index) and objective force-plate gait analysis (peak vertical force)." }, "cognitive-dysfunction": { "name": "Canine cognitive dysfunction syndrome", "short": "Age-related cognitive decline, the dog analogue of dementia.", "description": "Cognitive dysfunction syndrome presents as disorientation, altered social interaction, disrupted sleep, house-soiling in a previously trained dog, and reduced activity. It is under-diagnosed because owners often read the early signs as ordinary aging.", "measured_by": "Validated owner questionnaires (CADES, CCDR, DISHAA) and, in research settings, laboratory cognitive testing." }, "healthspan": { "name": "Lifespan and healthspan", "short": "Interventions aimed at aging itself rather than a single disease.", "description": "A new category: drugs and protocols intended to delay the onset of age-related disease across the board. Nothing here has completed a lifespan-endpoint trial in dogs yet, so this section is mostly about what is being tested and how to read the results when they arrive.", "measured_by": "Lifespan, healthspan indices, owner-reported quality of life, and biomarkers of aging. Trials are long and expensive, which is why evidence is thin." }, "mobility": { "name": "Mobility and muscle loss", "short": "Weakness, sarcopenia, and reduced activity independent of joint pain.", "description": "Aging dogs lose muscle mass and proprioceptive control even without significant arthritis. This overlaps heavily with osteoarthritis but responds to different interventions, and is frequently missed as a separate problem.", "measured_by": "Body condition and muscle condition scoring, accelerometry, sit-to-stand testing." }, "kidney-disease": { "name": "Chronic kidney disease", "short": "Progressive loss of kidney function, one of the most common serious diseases of older dogs.", "description": "Chronic kidney disease is usually well advanced before an owner notices anything, because the early signs are easy to read as ordinary aging: drinking more, urinating more, a little weight coming off. It is the condition the thirst measurement in the monitoring framework exists to catch, and it is one of the few places in geriatric medicine where a dietary change has a randomized trial showing a survival benefit.", "measured_by": "Serum creatinine and SDMA, urine specific gravity, urine protein to creatinine ratio, and blood pressure. IRIS staging combines these into a stage from 1 to 4, which is what treatment decisions hang on." } }, "monitoring": { "framework": { "name": "Senior Dog Longevity Monitoring Framework", "version": "0.1.0", "premise": "Most decline in aging dogs is caught late because nobody was measuring. A twice-yearly structured review across a fixed set of domains catches trends while they are still reversible, and turns a vague 'she's slowing down' into a dated number a veterinarian can act on.", "cadence_default": "Every 6 months from age 7 (or from age 5 for giant breeds), and every 3 months from age 11 or after any new diagnosis.", "how_to_use": "Score every domain at each review, even the ones that seem fine. The value is in the trend, not the snapshot. A domain that moves two levels between reviews matters more than a domain that has been mildly abnormal for years." }, "domains": [ { "id": "body-condition", "name": "Body weight, body condition, and muscle mass", "priority": "core", "direction": "higher_is_worse", "why": "Excess weight measurably worsens arthritis pain, and losing 6-9% of body weight reduces lameness on its own. Muscle loss is a separate problem that tracks with frailty and is routinely missed because a fat dog and a sarcopenic dog can weigh the same.", "measure": "Body weight in kg on the same scale; Body Condition Score (1-9); Muscle Condition Score (normal / mild / moderate / severe loss) assessed over the skull, scapulae, spine, and pelvis.", "instrument": "WSAVA Body Condition Score and Muscle Condition Score charts", "cadence": "Monthly weight at home; BCS and MCS at every review", "target": "BCS 4-5 of 9, with normal muscle condition", "red_flags": [ "Unexplained weight loss of more than 5% between reviews", "Muscle loss progressing while body weight stays flat", "Weight gain despite unchanged feeding" ], "links": [ "weight-optimization", "omega-3-fatty-acids" ] }, { "id": "mobility-pain", "name": "Mobility and chronic pain", "priority": "core", "direction": "higher_is_worse", "why": "Osteoarthritis is the most common source of chronic pain in older dogs and the best-studied condition in canine geriatric medicine. Owners consistently under-report it because they read it as ordinary aging rather than pain.", "measure": "A validated owner questionnaire scored the same way each time, plus three concrete observations: time to rise from lying, willingness to use stairs, and longest comfortable walk.", "instrument": "Canine Brief Pain Inventory (CBPI), LOAD, or Canine Orthopaedic Index. Pick one and stay with it", "cadence": "Every review; every 4 weeks when starting or changing a pain medication", "target": "Stable or improving score; any pain treatment should produce a measurable change or be reconsidered", "red_flags": [ "Reluctance to rise, or taking more than a few seconds to stand", "New avoidance of stairs, jumping, or slippery floors", "Night restlessness or panting at rest, both of which can be pain rather than anxiety", "Sudden worsening in a dog on an anti-NGF antibody, which cannot be withdrawn quickly" ], "links": [ "nsaids", "bedinvetmab", "grapiprant", "weight-optimization", "omega-3-fatty-acids" ] }, { "id": "cognition", "name": "Cognition and behavior", "priority": "core", "direction": "higher_is_worse", "why": "Cognitive dysfunction is under-diagnosed because early signs read as ordinary aging. It is also the domain where a baseline score matters most, since gradual change is invisible without one.", "measure": "A validated cognitive questionnaire covering disorientation, social interaction, sleep-wake cycle, house-training, activity, and anxiety.", "instrument": "CADES, CCDR, or DISHAA", "cadence": "Every review; at 30 and 90 days after starting a dietary or drug intervention", "target": "Stable score. The 2018 MCT diet trial measured change at 30 and 90 days, so judge interventions on that timescale rather than in weeks.", "red_flags": [ "Staring at walls, getting stuck in corners, or standing on the hinge side of doors", "Reversed day-night sleep pattern", "House-soiling in a previously reliable dog", "Failing to greet familiar people" ], "links": [ "mct-enriched-diet", "selegiline" ] }, { "id": "thirst-urination", "name": "Thirst, urination, and appetite", "priority": "core", "direction": "higher_is_worse", "why": "Increased drinking and urination is the earliest owner-detectable sign of kidney disease, diabetes, and Cushing's, three conditions where early detection changes the outcome substantially.", "measure": "Measured water intake in ml over 24 hours (not estimated), overnight accidents, and appetite change.", "instrument": "Household measuring jug; normal intake is roughly under 100 ml/kg/day and most healthy dogs drink well below that", "cadence": "A measured 24-hour water intake before each review, and any time you suspect a change", "target": "Stable intake appropriate to diet and weather", "red_flags": [ "Water intake above 100 ml/kg/day", "New overnight urination in a house-trained dog", "Appetite increase with weight loss, or appetite loss of more than a couple of days" ], "links": [ "renal-therapeutic-diet" ] }, { "id": "bloodwork", "name": "Bloodwork, urinalysis, and organ function", "priority": "core", "direction": "neutral", "why": "Every drug on this site that works long-term is limited by organ tolerance rather than by efficacy. NSAID use in particular requires a baseline and repeat monitoring, and kidney disease is usually well advanced before it is visible from the outside.", "measure": "Complete blood count, serum chemistry, urinalysis with urine specific gravity, and SDMA. Thyroid testing where signs suggest it.", "instrument": "Veterinary laboratory panel. Keep copies of every result so trends are visible across years", "cadence": "Annually as a baseline from age 7; every 6 months from age 11; within 2-4 weeks of starting an NSAID and every 3-6 months while on one", "target": "Values stable within reference range; a value drifting within the normal range still matters", "red_flags": [ "Rising creatinine or SDMA, even inside the reference interval", "Urine specific gravity falling toward 1.012", "New or rising liver enzymes in a dog on long-term medication" ], "links": [ "grapiprant", "nsaids", "renal-therapeutic-diet" ] }, { "id": "cardiorespiratory", "name": "Heart and breathing", "priority": "core", "direction": "higher_is_worse", "why": "Resting respiratory rate is the single most useful number an owner can collect at home, and a rise above 30 breaths per minute while sleeping is an early, actionable sign of congestive heart failure.", "measure": "Sleeping respiratory rate. Count chest rises for 30 seconds while the dog is asleep and double it. Note any cough, exercise intolerance, or fainting.", "instrument": "A phone timer, recorded weekly in a log", "cadence": "Weekly at home for any dog with a known murmur; monthly otherwise", "target": "Under 30 breaths per minute while sleeping", "red_flags": [ "Sleeping respiratory rate consistently above 30", "Any collapse or fainting episode, which needs same-day veterinary attention", "Cough that worsens at night, or reduced exercise tolerance" ], "links": [] }, { "id": "oral-health", "name": "Dental and oral health", "priority": "supporting", "direction": "higher_is_worse", "why": "Periodontal disease is painful, extremely common in older dogs, and frequently rationalized as 'old dog breath'. It is also one of the few sources of chronic pain that can be genuinely resolved rather than managed.", "measure": "Visual check of gums and teeth for tartar, recession, mobility, and masses; note breath odor, dropped food, and one-sided chewing.", "instrument": "Veterinary oral exam; conscious inspection at home between visits", "cadence": "Every review, with professional assessment annually", "red_flags": [ "Dropping food, chewing on one side, or reluctance to take hard treats", "Any oral mass", "Facial swelling below the eye, which suggests a tooth root abscess" ], "links": [] }, { "id": "masses", "name": "Lumps, masses, and skin", "priority": "supporting", "direction": "higher_is_worse", "why": "Cancer risk climbs steeply with age. A dated body map turns 'has this always been there?' into an answerable question, which is the difference between early and late detection.", "measure": "A full-body check with each mass logged by location and measured in mm, ideally photographed against a ruler.", "instrument": "Body map diagram with dated measurements", "cadence": "Monthly at home; every review with a veterinarian", "red_flags": [ "Any new mass, or an existing one that changes size, shape, or texture", "Masses that are fixed to underlying tissue, ulcerated, or growing quickly", "Any mass in a dog that is also losing weight" ], "links": [] }, { "id": "senses", "name": "Vision and hearing", "priority": "supporting", "direction": "higher_is_worse", "why": "Sensory loss mimics cognitive dysfunction almost exactly. A dog that ignores you may be deaf rather than demented, and the management is completely different. This must be excluded before a dementia diagnosis is accepted.", "measure": "Response to hand signals versus voice, navigation in dim light, startle response when approached from behind, bumping into furniture in unfamiliar places.", "instrument": "Structured observation; veterinary ophthalmic exam where change is suspected", "cadence": "Every review", "red_flags": [ "Bumping into things, especially in low light", "Cloudiness of the lens, or a visibly enlarged or reddened eye, which is urgent", "Not responding to a name that used to work reliably" ], "links": [ "mct-enriched-diet", "selegiline" ] }, { "id": "medication-review", "name": "Medication and supplement review", "priority": "core", "direction": "neutral", "why": "Geriatric dogs accumulate medications, and the interaction risks are real: selegiline with serotonergic drugs, NSAIDs with steroids or with a second NSAID. Reviews are also the moment to drop supplements that trials show do not work.", "measure": "A complete list of everything given, including supplements, chews, and over-the-counter products, with dose and reason.", "instrument": "Written medication list brought to every visit", "cadence": "Every review, and any time something is added", "red_flags": [ "Two NSAIDs, or an NSAID plus a corticosteroid", "An MAO inhibitor such as selegiline alongside tramadol or a serotonergic antidepressant", "Any supplement continued for over a year with no measured benefit" ], "links": [ "nsaids", "selegiline", "glucosamine-chondroitin" ] }, { "id": "quality-of-life", "name": "Quality of life", "priority": "core", "direction": "higher_is_better", "why": "The hardest decisions get made in crisis, at night, without a reference point. Scoring quality of life while the dog is doing well creates a baseline and forces the conversation to happen before it is urgent.", "measure": "Score hurt, hunger, hydration, hygiene, happiness, mobility, and whether good days outnumber bad, each scored 0 to 10.", "instrument": "HHHHHMM quality of life scale (Villalobos)", "cadence": "Every review; weekly in advanced disease or on hospice care", "target": "A total consistently above 35 of 70 is generally considered acceptable quality of life, but the trend and the owner's own read matter more than the threshold", "red_flags": [ "Bad days beginning to outnumber good days", "Any single category persistently at or below 3", "Loss of interest in the two or three things the dog has always loved most" ], "links": [] }, { "id": "activity", "name": "Activity and sleep", "priority": "supporting", "direction": "higher_is_better", "why": "Activity decline is often the first objective signal of pain or systemic illness, and it can be measured continuously rather than recalled. Sleep disruption cuts across pain, cognition, and cardiac disease.", "measure": "Daily activity from a collar accelerometer if available, otherwise total walk minutes per week; night waking episodes per week.", "instrument": "Activity monitor or a simple weekly log", "cadence": "Continuous where a device is used; otherwise a one-week log before each review", "red_flags": [ "A sustained drop in activity not explained by weather or routine", "Increased night waking or pacing", "Sleeping through activities that used to prompt engagement" ], "links": [ "nsaids", "weight-optimization" ] } ] }, "interventions": [ { "id": "nsaids", "name": "Veterinary NSAIDs (carprofen, meloxicam, firocoxib, robenacoxib)", "brand_names": [ "Rimadyl", "Metacam", "Previcox", "Onsior" ], "aliases": [ "non-steroidal anti-inflammatory drugs", "coxibs" ], "category": "nsaid", "conditions": [ "osteoarthritis", "mobility" ], "tier": "A", "tier_rationale": "This is the most replicated finding in canine osteoarthritis medicine. Multiple independent randomized controlled trials, including trials using objective force-plate outcomes rather than owner impressions, show significant improvement with carprofen and meloxicam where placebo and glucosamine-chondroitin produced none. Systematic reviews consistently rank NSAIDs as the best-supported pharmacological option.", "regulatory": { "us": "Multiple FDA-approved products for canine osteoarthritis pain and inflammation.", "eu": "Widely authorized.", "notes": "Human NSAIDs such as ibuprofen, naproxen, and aspirin are a different matter entirely and are dangerous to dogs. Never substitute them." }, "plain_summary": "The best-evidenced treatment for arthritis pain in dogs, and the benchmark every newer drug is measured against. The real limit is not whether they work but whether a given older dog's kidneys, liver, and gut can tolerate them long-term.", "what_trials_show": "Randomized trials using objective kinetic gait analysis found that measured variables improved significantly with carprofen and meloxicam, while a glucosamine-chondroitin product and placebo produced no significant improvement. That is a direct demonstration that the NSAID effect is more than regression to the mean or owner optimism. Effect sizes are clinically meaningful and appear within days rather than weeks. Comparative trials against newer agents such as bedinvetmab and grapiprant generally show similar pain control, with the differences showing up in the side-effect profile rather than in efficacy.", "harms": "Gastrointestinal ulceration and bleeding, kidney injury, and liver enzyme elevation. Risk rises with age, dehydration, pre-existing kidney disease, and concurrent steroid use. In one randomized comparison, the meloxicam arm recorded 17 adverse events versus 4 in the bedinvetmab arm, 9 of them gastrointestinal. Never combine an NSAID with a corticosteroid or with a second NSAID, and observe a washout when switching between NSAIDs.", "practical": { "route": "Oral, usually daily", "typical_course": "Ongoing, often with periodic attempts at the lowest effective dose", "monitoring": "Baseline bloodwork including kidney and liver values, repeated within 2-4 weeks of starting and then every 3-6 months. Stop and call the vet for vomiting, black stool, appetite loss, or increased drinking.", "cost_signal": "low" }, "ask_your_vet": [ "What were my dog's baseline kidney and liver values, and when do we recheck?", "Can we find the lowest effective dose rather than staying at the starting dose indefinitely?", "Which specific signs should make me stop the drug and call you the same day?", "Are any of my dog's other medications, especially steroids, incompatible with this?" ], "evidence": [ { "type": "rct", "citation": "Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Veterinary Record, 2003;152(11):323-9.", "year": 2003, "n": 71, "design": "Prospective, randomized, double-blind, placebo-controlled, four-arm", "blinding": "double-blind", "control": "Placebo, plus carprofen and meloxicam as active arms", "duration": "60 days", "population": "71 client-owned dogs over 20 kg with chronic stable osteoarthritis of the elbow, stifle, or hip", "primary_outcome": "Objective ground reaction forces on force-plate gait analysis, plus owner and orthopedic surgeon assessments", "result": "Dogs on meloxicam or carprofen showed significant improvement in ground reaction forces, with meloxicam returning values to normal baseline. The nutraceutical and placebo arms did not improve.", "funding": "See publication", "url": "https://pubmed.ncbi.nlm.nih.gov/12665145/", "summary": "The trial most worth citing when someone argues that arthritis improvement in dogs is all placebo. The NSAID arms separated from placebo on a force plate, which cannot be swayed by owner expectation." }, { "type": "systematic_review", "citation": "Pye C, et al. Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis. Journal of Small Animal Practice, 2024.", "year": 2024, "design": "Systematic review", "blinding": "not-applicable", "result": "Positions NSAIDs as the reference standard against which non-pharmaceutical options are judged, and finds most alternatives substantially less well supported.", "summary": "Useful for setting expectations about what non-drug approaches can and cannot replace.", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jsap.13670" }, { "type": "rct", "citation": "A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. 2025.", "year": 2025, "design": "Randomized, open-label, parallel-group", "blinding": "open-label", "control": "Bedinvetmab (active comparator)", "duration": "Multi-week", "population": "Client-owned dogs with osteoarthritis", "primary_outcome": "Canine Orthopaedic Index", "result": "Meloxicam produced a significant reduction in pain scores from baseline, statistically indistinguishable from bedinvetmab, but with more adverse events (17 versus 4).", "funding": "See publication", "summary": "Efficacy comparable to the newer biologic; the tradeoff is tolerability, not pain relief.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974340/" } ], "see_also": [ "bedinvetmab", "grapiprant", "omega-3-fatty-acids", "weight-optimization" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "bedinvetmab", "name": "Bedinvetmab (anti-NGF monoclonal antibody)", "brand_names": [ "Librela", "Beransa" ], "aliases": [ "anti-nerve growth factor antibody", "NGF mAb" ], "category": "biologic", "conditions": [ "osteoarthritis" ], "tier": "B", "tier_rationale": "Multiple randomized, placebo- and active-controlled trials show a real analgesic effect, and the pivotal trial was properly blinded and placebo-controlled. It is held at B rather than A because the placebo-adjusted response rate is moderate (43.5% vs 16.9% at day 28), the head-to-head comparison against meloxicam did not reach statistical significance for superiority, and an unresolved post-marketing safety signal around rapidly progressive osteoarthritis is under active discussion in the peer-reviewed literature.", "regulatory": { "us": "FDA-approved (2023) for control of osteoarthritis pain in dogs.", "eu": "EMA-authorized since 2020 as Librela.", "notes": "Approval means the regulator accepted the efficacy and safety package. It is not a claim that the drug is the best option for a given dog." }, "plain_summary": "A monthly injection that blocks a pain-signaling protein. It genuinely relieves arthritis pain in a substantial minority of dogs and avoids the gut and kidney risks of NSAIDs, but it is not reversible once injected and its long-term joint safety is actively debated.", "what_trials_show": "In the pivotal double-blind, placebo-controlled multisite trial, 43.5% of bedinvetmab-treated dogs met the predefined treatment-success threshold at day 28 versus 16.9% on placebo. That is a placebo-adjusted benefit of roughly 27 percentage points, meaning about one in four treated dogs improves because of the drug rather than because of time, attention, and owner expectation. In a randomized open-label comparison against meloxicam, both groups improved significantly from baseline on the Canine Orthopaedic Index; bedinvetmab's larger mean reduction was not statistically significant, so the honest reading is comparable efficacy with a different side-effect profile: 4 adverse events on bedinvetmab versus 17 on meloxicam, 9 of them gastrointestinal. A separate randomized non-inferiority trial using force-plate gait analysis compared it against grapiprant in a small cohort of 32 dogs.", "harms": "Injection-site reactions, and reports of neurological and mobility-related adverse events in post-marketing surveillance. The most serious open question is rapidly progressive osteoarthritis, meaning accelerated joint destruction of the kind seen with anti-NGF drugs in human trials, which halted their human development. A 2026 JAVMA paper argues this signal warrants vigilant adverse event reporting in dogs. Because the antibody persists for weeks, an adverse reaction cannot be stopped by discontinuing a daily pill. Discuss this openly rather than treating approval as settled reassurance.", "practical": { "route": "Subcutaneous injection given in-clinic", "typical_course": "Once monthly; effect is assessed over 2-3 cycles", "monitoring": "Baseline orthopedic exam, owner-completed pain score before starting and at each visit, and prompt reporting of any new limb weakness or sudden worsening", "cost_signal": "high" }, "ask_your_vet": [ "Has my dog been screened for the joint instability or neurological signs that would make me more cautious about anti-NGF treatment?", "What specific pain score are we measuring, and what change would count as this having failed?", "If we see accelerated joint damage, what is the plan given the drug cannot be withdrawn quickly?", "Would an NSAID trial be reasonable first for my dog, given their kidney and GI history?" ], "evidence": [ { "type": "rct", "citation": "Corral MJ, Moyaert H, Fernandes T, Escalada M, Tena JKS, Walters RR, Stegemann MR. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia, 2021;48(6):943-955.", "year": 2021, "design": "Prospective, randomized, blinded, placebo-controlled, multisite", "blinding": "double-blind", "control": "Placebo", "duration": "28 days to primary endpoint", "population": "287 client-owned dogs with osteoarthritis across 26 veterinary practices in four countries", "primary_outcome": "Owner-assessed treatment success on the Canine Brief Pain Inventory", "result": "43.5% treatment success with bedinvetmab versus 16.9% with placebo at day 28.", "funding": "Zoetis. The authors were Zoetis employees in Belgium and the United States.", "summary": "The pivotal registration trial. Well designed, properly blinded, and placebo controlled across 26 practices. The effect is real but moderate, and the study was designed, run, and written by the manufacturer.", "url": "https://pubmed.ncbi.nlm.nih.gov/34565678/", "n": 287 }, { "type": "rct", "citation": "A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. 2025.", "year": 2025, "design": "Randomized, open-label, multicentre, parallel-group active comparator", "blinding": "open-label", "control": "Meloxicam (active comparator)", "duration": "Multi-week", "population": "Client-owned dogs with osteoarthritis-related pain", "primary_outcome": "Change in Canine Orthopaedic Index score", "result": "Both groups improved significantly from baseline; bedinvetmab's larger mean reduction was not statistically significant. Adverse events: 4 (bedinvetmab) versus 17 (meloxicam), including 9 gastrointestinal events on meloxicam.", "funding": "Disclosed in source publication; open-label design is a meaningful limitation", "summary": "Suggests comparable pain control to a standard NSAID with fewer gastrointestinal events, but the lack of blinding inflates confidence in owner-reported outcomes.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11974340/" }, { "type": "rct", "citation": "A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis. Scientific Reports, 2026.", "year": 2026, "n": 32, "design": "Randomized, double-blind, non-inferiority", "blinding": "double-blind", "control": "Grapiprant (active comparator)", "duration": "Reported in source", "population": "Dogs with osteoarthritis", "primary_outcome": "Objective force-plate gait analysis", "result": "Compared bedinvetmab against grapiprant using an objective rather than owner-reported endpoint.", "funding": "See publication", "summary": "Valuable because force-plate analysis sidesteps the large placebo effect that contaminates owner-reported canine pain outcomes. Small sample limits precision.", "url": "https://www.nature.com/articles/s41598-026-37626-4" }, { "type": "safety_report", "citation": "Bedinvetmab (Librela/Beransa) in dogs raises safety concerns, including rapidly progressive osteoarthritis, and warrants vigilant adverse event reporting. Journal of the American Veterinary Medical Association, 2026.", "year": 2026, "design": "Commentary and pharmacovigilance analysis", "blinding": "not-applicable", "result": "Argues that post-marketing reports, including rapidly progressive osteoarthritis, justify heightened surveillance and franker owner consent discussions.", "summary": "The most important counterweight to the registration trials. Read this before assuming approval settles the safety question.", "url": "https://avmajournals.avma.org/view/journals/javma/aop/javma.26.03.0170/javma.26.03.0170.xml" } ], "see_also": [ "nsaids", "grapiprant" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "grapiprant", "name": "Grapiprant (EP4 prostaglandin receptor antagonist)", "brand_names": [ "Galliprant" ], "aliases": [ "piprant" ], "category": "analgesic", "conditions": [ "osteoarthritis" ], "tier": "B", "tier_rationale": "One large, well-conducted, randomized, masked, placebo-controlled multisite trial (285 dogs enrolled, 262 evaluable) demonstrated significant improvement over placebo on owner-reported pain, and it has since been used as an active comparator in blinded trials. It sits at B rather than A because the independent replication base is thinner than for traditional NSAIDs and the pivotal evidence is manufacturer-funded.", "regulatory": { "us": "FDA-approved (2016) for control of pain and inflammation associated with canine osteoarthritis.", "notes": "Approved on the strength of the Rausch-Derra pivotal field study." }, "plain_summary": "A targeted pain drug that blocks one specific inflammatory receptor rather than shutting down prostaglandin production broadly. Often chosen for older dogs where the broader gastrointestinal and kidney effects of a classic NSAID are the main worry.", "what_trials_show": "In the pivotal 16-site randomized masked placebo-controlled study, 285 client-owned dogs with osteoarthritis were enrolled and 262 were evaluable, split evenly between grapiprant at 2 mg/kg daily and placebo. Owners scored their dogs on the Canine Brief Pain Inventory at days 0, 7, 14, 21, and 28. Both pain interference and pain severity improved significantly relative to placebo. The trial was properly masked, which matters a great deal in a field where owner-reported placebo response routinely runs above 15%.", "harms": "Generally well tolerated, with vomiting and soft stool the most common effects. Because it spares the prostaglandin pathways involved in gastric protection and kidney perfusion more than traditional NSAIDs do, it is often preferred where those risks dominate. But that is a mechanistic argument, and head-to-head long-term safety data in geriatric dogs with kidney disease remains limited. Do not combine with an NSAID or corticosteroid.", "practical": { "route": "Oral tablet", "typical_course": "2 mg/kg once daily, on an empty stomach", "monitoring": "Baseline bloodwork and periodic rechecks; watch appetite and stool quality", "cost_signal": "moderate" }, "ask_your_vet": [ "Is grapiprant preferable to a traditional NSAID given my dog's specific kidney and GI history, or is that mostly theoretical here?", "What pain score are we tracking, and at what point do we call it ineffective and switch?", "Would combining this with weight loss and omega-3s let us use a lower dose?" ], "evidence": [ { "type": "rct", "citation": "Rausch-Derra L, Huebner M, Wofford J, Rhodes L. A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis. Journal of Veterinary Internal Medicine, 2016;30(3):756-763.", "year": 2016, "n": 262, "design": "Prospective, randomized, masked, placebo-controlled, 16-site field study", "blinding": "double-blind", "control": "Placebo", "duration": "28 days", "population": "285 client-owned dogs with osteoarthritis enrolled; 262 evaluable, 131 per group", "primary_outcome": "Owner-completed Canine Brief Pain Inventory success at day 28", "result": "Statistically significant improvement in both pain interference and pain severity versus placebo.", "funding": "Aratana Therapeutics (manufacturer)", "summary": "The pivotal registration study and still the strongest single piece of evidence for this drug. Large, masked, placebo-controlled, and multisite. A genuinely good trial, with the standard caveat that the sponsor ran it.", "url": "https://pubmed.ncbi.nlm.nih.gov/27075237/" }, { "type": "rct", "citation": "A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis. Scientific Reports, 2026.", "year": 2026, "n": 32, "design": "Randomized, double-blind, non-inferiority", "blinding": "double-blind", "control": "Bedinvetmab (active comparator)", "duration": "See publication", "population": "Dogs with osteoarthritis", "primary_outcome": "Force-plate gait analysis", "result": "Grapiprant served as the active comparator against the anti-NGF biologic on an objective endpoint.", "funding": "See publication", "summary": "Being chosen as the comparator in an objective-endpoint trial reflects that grapiprant is now treated as an established standard rather than a novelty.", "url": "https://www.nature.com/articles/s41598-026-37626-4" } ], "see_also": [ "nsaids", "bedinvetmab" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "mct-enriched-diet", "name": "Medium-chain triglyceride (MCT) enriched diet", "brand_names": [ "Purina Pro Plan Bright Mind", "Hill's b/d" ], "aliases": [ "MCT oil diet", "brain protection blend" ], "category": "diet", "conditions": [ "cognitive-dysfunction" ], "tier": "B", "tier_rationale": "A randomized, double-blind, placebo-controlled, multi-site trial with 87 dogs in three arms of 29 found significant improvement in all six categories of cognitive dysfunction signs on the 6.5% MCT diet. That is a genuinely good trial design for this field. It is held at B because independent replication outside manufacturer-supported work is limited and the outcome is an owner-completed questionnaire rather than an objective measure.", "regulatory": { "us": "Marketed as therapeutic or wellness diets rather than drugs.", "notes": "Dietary claims are not held to the evidentiary standard applied to pharmaceuticals, which makes the existence of a real randomized trial here notable rather than expected." }, "plain_summary": "The best-evidenced intervention for canine dementia, and one of the few places where a diet change has randomized trial support. Medium-chain triglycerides give the aging brain an alternative fuel source when its glucose metabolism falters.", "what_trials_show": "The key trial was a randomized, double-blind, placebo-controlled, multi-site study run through participating veterinary clinics. Eighty-seven dogs were randomized into three arms of 29: a control diet, a 6.5% MCT oil diet with a brain protection blend, and a 9% MCT diet. Diets were fed for 90 days with reassessment of cognitive dysfunction signs at days 30 and 90. All six categories of cognitive dysfunction signs improved significantly in the 6.5% MCT group by the end of the study. The higher 9% dose did not simply do more, a reminder that more is not better here. A broader systematic review of enriched diets and nutraceuticals for cognitive enhancement in aged dogs and cats supports the direction of this finding, and a scoping review found that combining supplemented diets with environmental enrichment improved signs more than either alone.", "harms": "Well tolerated. MCT diets are calorie-dense, so watch weight. That matters because excess weight worsens the arthritis many of these same dogs have. Transition gradually to avoid loose stool. Not a substitute for investigating other causes of behavior change: pain, hearing and vision loss, endocrine disease, and hypertension all mimic cognitive dysfunction and are treatable.", "practical": { "route": "Complete therapeutic diet, or MCT oil added to food", "typical_course": "Judge at 90 days, since the trial saw effects by day 30 and clearer separation by day 90", "monitoring": "Use a validated owner questionnaire such as CADES or DISHAA at baseline and at 30 and 90 days, so you are measuring rather than guessing", "cost_signal": "moderate" }, "ask_your_vet": [ "Before we call this dementia, have we ruled out pain, hearing and vision loss, and endocrine disease?", "Can we score my dog on CADES or DISHAA now so we have a real baseline to compare against at 90 days?", "Would adding structured enrichment and exercise alongside the diet be worthwhile, given the scoping review found the combination better?", "How do we fit these calories into my dog's weight target?" ], "evidence": [ { "type": "rct", "citation": "Pan Y, Landsberg G, Mougeot I, Kelly S, Xu H, Bhatnagar S, Gardner CL, Milgram NW. Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study. Frontiers in Nutrition, 2018;5:127.", "year": 2018, "n": 87, "design": "Randomized, double-blind, placebo-controlled, multi-site, three parallel arms of 29 dogs", "blinding": "double-blind", "control": "Control diet", "duration": "90 days, with assessment at days 30 and 90", "population": "Dogs with signs of cognitive dysfunction syndrome", "primary_outcome": "Owner-assessed cognitive dysfunction signs across six categories", "result": "All six categories of cognitive dysfunction signs improved significantly in the 6.5% MCT diet group at 90 days. The 9% MCT arm did not outperform it.", "funding": "Nestlé Purina", "summary": "The strongest single trial in canine cognitive dysfunction. Properly blinded and placebo-controlled across 24 sites; manufacturer-funded, and the endpoint is owner-reported.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299068/" }, { "type": "systematic_review", "citation": "Enhancing cognitive functions in aged dogs and cats: a systematic review of enriched diets and nutraceuticals. GeroScience, 2025.", "year": 2025, "design": "Systematic review", "blinding": "not-applicable", "result": "Reviews the dietary and nutraceutical evidence base for cognitive support in aged dogs and cats.", "summary": "Places the MCT finding in the context of the wider, and largely weaker, nutraceutical literature.", "url": "https://link.springer.com/article/10.1007/s11357-025-01521-z" }, { "type": "systematic_review", "citation": "Non-pharmacological interventions for the treatment of canine cognitive dysfunction: A scoping review. Applied Animal Behaviour Science, 2023.", "year": 2023, "design": "PRISMA-ScR scoping review", "blinding": "not-applicable", "result": "Found that combining supplemented diets with environmental enrichment improves signs of canine cognitive dysfunction.", "summary": "Supports pairing the diet with enrichment rather than relying on food alone.", "url": "https://www.sciencedirect.com/science/article/pii/S0168159123002691" } ], "see_also": [ "selegiline" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "omega-3-fatty-acids", "name": "Omega-3 fatty acids (EPA/DHA-enriched diets and fish oil)", "brand_names": [], "aliases": [ "fish oil", "EPA", "DHA", "marine omega-3" ], "category": "diet", "conditions": [ "osteoarthritis", "mobility" ], "tier": "B", "tier_rationale": "Several independent randomized, double-blinded, controlled trials, including multicentre studies with over 100 dogs and one using objective force-plate weight-bearing as the endpoint, show consistent, modest benefit. It falls short of A because effect sizes are small relative to NSAIDs, several trials were manufacturer-funded, and the 2022 meta-analysis of nutraceuticals found the overall nutraceutical literature uneven even while treating omega-3s more favorably than most.", "regulatory": { "us": "Sold as therapeutic diets and supplements; supplements are not held to drug-level manufacturing standards.", "notes": "Dose and EPA/DHA concentration vary enormously between products. A generic 'fish oil' capsule may deliver a fraction of the therapeutic-diet dose used in trials." }, "plain_summary": "One of the very few supplements with real randomized evidence behind it. Expect a modest improvement in mobility and, importantly, the possibility of getting the same pain control on a lower NSAID dose. It is not a replacement for pain medication.", "what_trials_show": "In a randomized, double-blinded, controlled trial of 38 client-owned dogs, food containing 3.5% fish oil omega-3s improved mean peak vertical force by 5.6% between day 0 and day 90, versus 0.4% in the control group. Peak vertical force is an objective force-plate measure of how much weight the dog is willing to put on the limb. A separate randomized, double-blinded, controlled trial across 18 veterinary clinics enrolled 127 client-owned dogs on a food with a 31-fold increase in total omega-3 content and a 34-fold reduction in the omega-6 to omega-3 ratio over six months. A third randomized, controlled, multisite trial at 33 veterinary hospitals with 131 client-owned dogs specifically examined whether omega-3 supplementation reduced the carprofen dose required. That is the most practically useful endpoint of the three, since NSAID dose reduction directly reduces long-term organ risk.", "harms": "Well tolerated at typical doses. High doses can cause loose stool, fishy odor, and in theory altered platelet function, which matters if surgery is planned. Oil quality and rancidity are genuine concerns in unregulated supplements. Cod liver oil is a poor choice as a high-dose source because of vitamin A and D content.", "practical": { "route": "Therapeutic diet or oil/capsule supplement", "typical_course": "Ongoing; trials measured benefit at 90 days and beyond, so judge it at three months, not three weeks", "monitoring": "Body condition score, since these are calorie-dense; tell your surgeon before any procedure", "cost_signal": "moderate" }, "ask_your_vet": [ "What actual EPA and DHA dose in milligrams should my dog get, rather than a number of capsules?", "Could adding this let us reduce the NSAID dose, and how would we test that safely?", "Is a therapeutic diet a better delivery route than capsules for my dog's calorie budget?" ], "evidence": [ { "type": "rct", "citation": "Roush JK, Cross AR, Renberg WC, Dodd CE, Sixby KA, Fritsch DA, Allen TA, Jewell DE, Richardson DC, Leventhal PS, Hahn KA. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. JAVMA, 2010;236(1):67-73.", "year": 2010, "n": 38, "design": "Randomized, double-blinded, controlled clinical trial", "blinding": "double-blind", "control": "Control food", "duration": "90 days", "population": "38 client-owned dogs with osteoarthritis at two university veterinary clinics", "primary_outcome": "Peak vertical force on force-plate gait analysis", "result": "Mean peak vertical force improved 5.6% in the test-food group versus 0.4% in controls between days 0 and 90, significant for the test group only. 82% of test-food dogs showed improved weight bearing against 38% of controls.", "funding": "Hill's Pet Nutrition", "summary": "The most persuasive entry because the endpoint is objective. Manufacturer-funded, and the effect is modest. But it is measured, not reported by hopeful owners.", "url": "https://pubmed.ncbi.nlm.nih.gov/20043801/" }, { "type": "rct", "citation": "A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. 2010.", "year": 2010, "n": 131, "design": "Randomized, controlled, multisite (33 veterinary hospitals)", "blinding": "double-blind", "control": "Control food", "duration": "Multi-month", "population": "Client-owned dogs with stable chronic osteoarthritis", "primary_outcome": "Carprofen dosage requirement", "result": "Examined whether omega-3 supplementation permitted reduced carprofen dosing.", "funding": "Industry-supported", "summary": "The dose-sparing question is the clinically important one for geriatric dogs, since lower NSAID exposure means lower cumulative kidney and GI risk.", "url": "https://pubmed.ncbi.nlm.nih.gov/20187817/" }, { "type": "rct", "citation": "Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. 2010.", "year": 2010, "n": 127, "design": "Randomized, double-blinded, controlled", "blinding": "double-blind", "control": "Control food", "duration": "6 months", "population": "Client-owned dogs with osteoarthritis across 18 clinics", "primary_outcome": "Owner- and veterinarian-assessed osteoarthritis signs", "result": "Test food with a 31-fold higher total omega-3 content and 34-fold lower omega-6:omega-3 ratio was assessed over six months.", "funding": "Industry-supported", "summary": "Longer follow-up than most canine osteoarthritis trials, which typically stop at 28-90 days.", "url": "https://pubmed.ncbi.nlm.nih.gov/20043800/" }, { "type": "meta_analysis", "citation": "Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. International Journal of Molecular Sciences, 2022;23(18):10384.", "year": 2022, "design": "Systematic review and meta-analysis. 1578 publications screened, 57 articles included, comprising 72 trials across nine categories of natural health compound.", "blinding": "not-applicable", "result": "Found omega-3-enriched diets among the better-supported nutritional interventions, in sharp contrast to chondroitin-glucosamine, which showed a marked non-effect.", "summary": "The single most useful reference for separating nutraceuticals that work from those that do not.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499673/", "funding": "Université de Montréal research groups (GREPAQ and CHUM arthrosis unit); see publication" } ], "see_also": [ "nsaids", "glucosamine-chondroitin", "weight-optimization" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "renal-therapeutic-diet", "name": "Therapeutic renal diet", "brand_names": [ "Hill's k/d", "Royal Canin Renal", "Purina NF" ], "aliases": [ "kidney diet", "renal food", "protein and phosphorus restricted diet" ], "category": "diet", "conditions": [ "kidney-disease" ], "tier": "B", "tier_rationale": "One double-masked, randomized, controlled trial in dogs with a survival endpoint, which is close to the strongest study design this field produces. Dogs fed the renal food lived at least 13 months longer than dogs fed maintenance food, and uremic crises were delayed by roughly 5 months. It is held at B rather than A because that is a single trial of 38 dogs. The equivalent trial in cats found the same direction of effect, which is reassuring but is not evidence in dogs.", "regulatory": { "us": "Sold as veterinary therapeutic diets, available through veterinarians rather than as regulated drugs.", "notes": "Dietary claims are not held to the evidentiary standard applied to pharmaceuticals, which makes a randomized survival trial in this category genuinely unusual." }, "plain_summary": "The best-evidenced treatment for canine kidney disease, and one of the very few interventions anywhere in geriatric veterinary medicine shown in a randomized trial to extend life rather than just relieve symptoms. The hard part is not whether it works, it is getting a dog with a poor appetite to eat it.", "what_trials_show": "In a double-masked, randomized, controlled trial, 38 dogs with spontaneous chronic renal failure were assigned to either a standard adult maintenance food or a therapeutic renal food, and followed for up to 24 months. Dogs fed the renal food lived at least 13 months longer than those fed maintenance food. In dogs with a lesser degree of azotemia, the renal food delayed the onset of uremic crises by roughly 5 months. Those are survival and hard-event endpoints rather than owner-reported comfort scores, which is what makes this trial unusual. A separately conducted double-masked randomized trial of 45 cats with stage 2 or 3 chronic kidney disease found the same direction of effect, but cats are not dogs and that trial is context rather than evidence here.", "harms": "The real risk is not toxicity, it is that the dog will not eat. Renal diets restrict protein, phosphorus, and sodium, and dogs with kidney disease often have poor appetite and nausea to begin with. A dog that refuses the diet and eats less overall can lose weight and muscle, which is worse than the diet not being restricted at all. Protein restriction in a dog that does not yet need it is also not benign. This is a treatment to start on veterinary advice at the right IRIS stage, not something to move to early on suspicion.", "practical": { "route": "Complete therapeutic diet, replacing the normal food", "typical_course": "Ongoing, typically introduced from IRIS stage 2 or 3 onward", "monitoring": "Body weight and muscle condition at every visit, since appetite loss is the main failure mode, plus creatinine, SDMA, urine specific gravity, and phosphorus on the schedule your vet sets", "cost_signal": "moderate" }, "ask_your_vet": [ "What IRIS stage is my dog, and is that the stage where a renal diet is indicated?", "If they will not eat it, what are the alternatives, and is a partial switch worth anything?", "How will we tell the diet is helping rather than just assuming it is?", "Should we be treating phosphorus or blood pressure alongside the diet?" ], "evidence": [ { "type": "rct", "citation": "Jacob F, Polzin DJ, Osborne CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic renal failure in dogs. JAVMA, 2002;220(8):1163-1170.", "year": 2002, "n": 38, "design": "Double-masked, randomized, controlled clinical trial", "blinding": "double-blind", "control": "Standard adult maintenance food", "duration": "Up to 24 months", "population": "38 dogs with spontaneous chronic renal failure", "primary_outcome": "Uremic crises and mortality", "result": "Dogs fed the renal food lived at least 13 months longer than those fed maintenance food. In dogs with less severe azotemia, uremic crises were delayed by approximately 5 months.", "funding": "Hill's Pet Nutrition supported the work; see publication for the full disclosure", "summary": "The load-bearing trial for this entry, and one of the few randomized trials in canine geriatric medicine with a survival endpoint. Manufacturer-supported and small at 38 dogs, but properly double-masked and randomized.", "url": "https://pubmed.ncbi.nlm.nih.gov/11990962/" }, { "type": "rct", "citation": "Ross SJ, Osborne CA, Kirk CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. JAVMA, 2006;229(6):949-957.", "year": 2006, "n": 45, "design": "Double-masked, randomized, controlled clinical trial", "blinding": "double-blind", "control": "Adult maintenance diet", "duration": "Up to 24 months, evaluated trimonthly", "population": "45 client-owned cats with spontaneous stage 2 or 3 chronic kidney disease", "primary_outcome": "Uremic episodes and mortality", "result": "A renal diet modified in protein, phosphorus, sodium, and lipid content reduced uremic episodes and mortality relative to maintenance diet.", "funding": "Hill's Pet Nutrition supported the work; see publication", "summary": "Included as context, not as evidence in dogs. It is listed because it is frequently cited in discussions of canine kidney diets, and readers should be able to see plainly that it was done in cats.", "url": "https://pubmed.ncbi.nlm.nih.gov/16978113/" } ], "see_also": [ "weight-optimization", "nsaids" ], "last_reviewed": "2026-08-13", "contributors": [ "@lextechx" ] }, { "id": "weight-optimization", "name": "Weight optimization (calorie-restricted weight loss)", "brand_names": [], "aliases": [ "weight loss", "body condition management" ], "category": "lifestyle", "conditions": [ "osteoarthritis", "mobility" ], "tier": "B", "tier_rationale": "Prospective controlled trials consistently show that weight loss alone reduces lameness, with a dose-response relationship: improvement appears from about 6% body weight reduction and confirmed on objective gait analysis from about 8.85%. It is held at B rather than A because the landmark studies are small (9 and 14 dogs) and open-label by necessity, since you cannot blind an owner to their dog getting thinner. The consistency and the objective kinetic confirmation are what keep it well above the supplement tier.", "regulatory": { "notes": "Not a regulated product. This is the intervention with the best benefit-to-risk ratio on this entire site and it costs nothing." }, "plain_summary": "The single most underused treatment for arthritis in older dogs. Losing roughly 6-9% of body weight measurably reduces lameness on its own, before any drug is added. And unlike every drug here, the side effects are all good ones.", "what_trials_show": "In a prospective clinical trial of 14 obese client-owned dogs with clinical and radiographic osteoarthritis, a restricted-calorie diet over 16 weeks with six follow-up visits produced a significant decrease in lameness from a body weight reduction of 6.10% onward, measured on numeric rating and visual analogue scales. Objective kinetic gait analysis confirmed the improvement from a body weight reduction of 8.85% onward. That is the important detail, because kinetic gait analysis cannot be influenced by an owner's hope that the diet is working. An earlier study of 9 dogs with radiographic hip osteoarthritis weighing 11-12% above ideal found significant improvement in lameness after 19 weeks, with dogs losing 11-18% of body weight. The dose-response pattern across both studies is what makes this credible: more weight off, less lameness.", "harms": "Essentially none when done properly. The real risks are procedural: crash dieting risks muscle loss in a geriatric dog that needs its remaining muscle, and unexplained weight loss in an old dog must be distinguished from disease before it is celebrated. Weight loss should be deliberate, measured, and roughly 1-2% of body weight per week.", "practical": { "route": "Measured calorie restriction, ideally with a therapeutic weight-loss diet so protein and micronutrients stay adequate", "typical_course": "16-19 weeks in the published trials; benefit begins well before target weight is reached", "monitoring": "Weigh on the same scale every 2 weeks, track body condition score and muscle condition score separately, and reassess lameness formally rather than by impression", "cost_signal": "low" }, "ask_your_vet": [ "What is my dog's ideal body weight in kilograms, and what is the target calorie intake to get there?", "Can we score body condition and muscle condition separately so we lose fat rather than muscle?", "Can we re-measure lameness at 6% and 9% weight loss to see whether it is working?", "Are treats and chews included in the calorie calculation?" ], "evidence": [ { "type": "rct", "citation": "Marshall WG, et al. The effect of weight loss on lameness in obese dogs with osteoarthritis. Veterinary Research Communications, 2010.", "year": 2010, "n": 14, "design": "Open prospective clinical trial with serial within-subject objective measurement", "blinding": "open-label", "control": "Within-subject baseline; dose-response across weight-loss increments", "duration": "16 weeks with six follow-up visits", "population": "Obese client-owned dogs with clinical and radiographic osteoarthritis", "primary_outcome": "Lameness by numeric rating scale, visual analogue scale, and kinetic gait analysis", "result": "Significant decrease in lameness from 6.10% body weight reduction onward; kinetic gait analysis confirmed improvement from 8.85% onward.", "funding": "See publication", "summary": "The first study to assess weight loss alone, both subjectively and objectively. Small and unblinded, but the objective dose-response is hard to explain away as expectation.", "url": "https://link.springer.com/article/10.1007/s11259-010-9348-7" }, { "type": "rct", "citation": "Impellizeri JA, Tetrick MA, Muir P. Effect of weight reduction on clinical signs of lameness in dogs with hip osteoarthritis.", "year": 2000, "n": 9, "design": "Prospective clinical trial", "blinding": "open-label", "control": "Within-subject baseline", "duration": "19 weeks", "population": "Client-owned dogs with radiographic hip osteoarthritis, 11-12% above ideal body weight", "primary_outcome": "Subjective lameness score", "result": "Significant improvement in lameness after 19 weeks; dogs lost 11-18% of body weight.", "funding": "See publication", "summary": "Very small and subjective, but directionally consistent with the later objective work.", "url": "https://www.researchgate.net/publication/12561078_Effect_of_weight_reduction_on_clinical_signs_of_lameness_in_dogs_with_hip_osteoarthritis" }, { "type": "systematic_review", "citation": "Pye C, et al. Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis. Journal of Small Animal Practice, 2024.", "year": 2024, "design": "Systematic review", "blinding": "not-applicable", "result": "Identifies weight management as among the best-supported non-pharmaceutical interventions for canine osteoarthritis.", "summary": "Independent confirmation that this belongs at the top of the non-drug list.", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jsap.13670" } ], "see_also": [ "nsaids", "omega-3-fatty-acids" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "selegiline", "name": "Selegiline (L-deprenyl)", "brand_names": [ "Anipryl" ], "aliases": [ "MAO-B inhibitor", "deprenyl" ], "category": "neuro", "conditions": [ "cognitive-dysfunction" ], "tier": "C", "tier_rationale": "Selegiline is the only FDA-approved drug for canine cognitive dysfunction and is the pharmaceutical most often reached for in practice, but the controlled trial base is older, smaller, and less rigorously reported than the modern MCT diet trial. The reported benefits of improved sleep, house-training, and activity come from trials that predate current validated cognitive scoring instruments. C reflects limited rather than absent evidence, not a judgment that it fails.", "regulatory": { "us": "FDA-approved 10 December 1998 for canine cognitive dysfunction syndrome, the only drug with that indication. Also approved for pituitary-dependent hyperadrenocorticism.", "notes": "Regulatory approval here reflects an older evidentiary era. Approval status and evidence strength are not the same thing, in either direction." }, "plain_summary": "The only approved drug for canine dementia. Worth trying, particularly for disrupted sleep and lost house-training, but set expectations modestly and pair it with a diet change and enrichment rather than relying on it alone.", "what_trials_show": "Clinical trials supporting approval showed improvement in sleeping, house-training, and activity in treated dogs. A 2025 survey of US practice found that when clinicians manage cognitive dysfunction pharmacologically, selegiline is the drug most often recommended, reflecting its unique approval status as much as its measured effect size. The trials underpinning it are not directly comparable to the modern multi-site randomized dietary work, because they used earlier outcome measures and smaller samples; anyone claiming a clean head-to-head between selegiline and an MCT diet is overstating what exists.", "harms": "Generally well tolerated. Vomiting, diarrhea, restlessness, and agitation occur. The important issue is drug interactions: as a monoamine oxidase inhibitor, selegiline must not be combined with other MAO inhibitors including amitraz, and combination with certain antidepressants, opioids such as tramadol, or serotonergic drugs risks serotonin syndrome. Review the entire medication list, because geriatric dogs are frequently on several drugs at once.", "practical": { "route": "Oral, once daily in the morning", "typical_course": "A trial of 4-8 weeks is reasonable before judging response; some dogs need up to 2 months", "monitoring": "Score cognition with a validated instrument at baseline and at follow-up; review all concurrent medications for serotonergic interactions before starting", "cost_signal": "moderate" }, "ask_your_vet": [ "Do any of my dog's current medications interact with an MAO inhibitor?", "How long should we give this before deciding it has not worked?", "Should we run this alongside an MCT diet and enrichment rather than as a standalone?", "Have we excluded pain, sensory loss, and endocrine disease as the real driver of these behavior changes?" ], "evidence": [ { "type": "regulatory", "citation": "FDA approval of selegiline hydrochloride (Anipryl), NADA 141-096, approved 10 December 1998 for control of clinical signs associated with canine cognitive dysfunction syndrome.", "year": 1998, "design": "Registration clinical trials", "blinding": "unclear", "control": "Placebo", "result": "Improvement reported in sleeping, house-training, and activity.", "funding": "Manufacturer", "summary": "The basis for the only drug approval in this indication. Older trials with outcome measures that predate today's validated cognitive scales.", "url": "https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/614" }, { "type": "observational", "citation": "Current practices for diagnosis and management of Canine Cognitive Dysfunction Syndrome in the United States. Frontiers in Veterinary Science, 2025.", "year": 2025, "design": "Practice survey", "blinding": "not-applicable", "result": "Selegiline is the pharmaceutical most often recommended by US clinicians managing canine cognitive dysfunction.", "summary": "Describes what practitioners do, which is not the same as what the evidence establishes. Included to make that distinction explicit.", "url": "https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1685430/full" } ], "see_also": [ "mct-enriched-diet" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "loy-002", "name": "LOY-002 (senior dog lifespan extension drug)", "brand_names": [], "aliases": [ "Loyal senior dog drug" ], "category": "investigational", "conditions": [ "healthspan" ], "tier": "U", "tier_rationale": "No peer-reviewed efficacy trial has been published. What exists is a regulatory milestone: the FDA accepted a Reasonable Expectation of Effectiveness in early 2025 and the Target Animal Safety section in January 2026, leaving manufacturing as the remaining section before possible conditional approval. Conditional approval is a specific regulatory pathway that permits marketing while full effectiveness data is still being gathered, which is exactly why this cannot be graded above U yet.", "regulatory": { "us": "Not approved. Two of three technical sections accepted by FDA CVM toward conditional approval. Conditional approval possible as early as late 2026 or 2027 if the manufacturing section proceeds without setbacks.", "notes": "Understand what conditional approval means before treating it as a green light: it allows marketing while the sponsor continues to gather the full effectiveness data. It is a bet the regulator permits, not a conclusion the regulator has reached." }, "plain_summary": "A daily pill in development that aims to extend healthy lifespan in senior dogs, targeting about one additional year. It is closer to market than anything comparable, but no published trial has yet shown it does this, and the approval pathway it is on does not require that proof up front.", "what_trials_show": "There is no published peer-reviewed efficacy trial to summarize. The developer's stated target is roughly one additional year of healthy life. In February 2025 the FDA accepted the Reasonable Expectation of Effectiveness technical section, and in January 2026 accepted the Target Animal Safety section, leaving the manufacturing section outstanding. If approved, it would be the first drug approved for lifespan extension itself in any species. Everything currently public about its effectiveness comes from company communications and regulatory milestone announcements rather than from independent published trial data. That is a distinction worth holding onto given how this is likely to be marketed.", "harms": "The FDA's acceptance of the Target Animal Safety section indicates the agency found the safety package adequate for this stage, which is meaningful. Independent long-term safety data in the general senior dog population does not yet exist, and by the nature of conditional approval will accumulate after marketing begins rather than before.", "practical": { "route": "Daily oral tablet (prescription, if approved)", "typical_course": "Ongoing daily administration in senior dogs", "monitoring": "To be established at approval", "cost_signal": "varies" }, "ask_your_vet": [ "If this becomes conditionally approved, what effectiveness data will actually exist at that point?", "Would you wait for the full effectiveness data, and why or why not?", "What proven interventions should we already be doing for my senior dog while this plays out?" ], "evidence": [ { "type": "regulatory", "citation": "Loyal Receives FDA Acceptance of Safety Package for Senior Dog Lifespan Extension Drug. Business Wire, January 2026.", "year": 2026, "design": "Regulatory milestone announcement", "blinding": "not-applicable", "result": "FDA CVM accepted the Target Animal Safety technical section for LOY-002, the second of three sections required for conditional approval.", "funding": "Company announcement", "summary": "A real regulatory step, and not the same thing as published evidence of effectiveness.", "url": "https://www.businesswire.com/news/home/20260113476778/en/Loyal-Receives-FDA-Acceptance-of-Safety-Package-for-Senior-Dog-Lifespan-Extension-Drug" }, { "type": "regulatory", "citation": "Loyal Receives FDA Acceptance of Reasonable Expectation of Effectiveness for Senior Dog Lifespan Extension. February 2025.", "year": 2025, "design": "Regulatory milestone announcement", "blinding": "not-applicable", "result": "FDA accepted the Reasonable Expectation of Effectiveness section, the standard for conditional approval, which is lower than the substantial-evidence standard for full approval.", "summary": "The precise wording matters: a reasonable expectation of effectiveness is not a demonstration of effectiveness.", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2025-2-26-loyal-receives-fda-acceptance-of-reasonable-expectation-of-effectiveness-for-senior-dog-lifespan-extension" }, { "type": "regulatory", "citation": "Lifespan extension drug in development for senior dogs reaches a new milestone. dvm360, 2026.", "year": 2026, "design": "Trade press report", "blinding": "not-applicable", "result": "Reports the milestone and the remaining manufacturing section, with conditional approval possible as early as late 2026 or 2027.", "summary": "Useful for timeline expectations.", "url": "https://www.dvm360.com/view/lifespan-extension-drug-in-development-for-senior-dogs-reaches-a-new-milestone" } ], "see_also": [ "rapamycin" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "rapamycin", "name": "Rapamycin (sirolimus) for healthy aging", "brand_names": [ "Rapamune" ], "aliases": [ "sirolimus", "mTOR inhibitor" ], "category": "investigational", "conditions": [ "healthspan" ], "tier": "U", "tier_rationale": "The definitive trial is running but has not reported. TRIAD is a properly randomized, placebo-controlled, multicentre trial with lifespan and healthspan endpoints, but as of mid-2026 it has enrolled roughly 180 of a target 580 dogs and only a few have completed the full three-year period. Published TRIAD output so far is baseline cohort description, not outcome data. Tier U means untested, not disproven. This is the most scientifically serious longevity effort in dogs, and it deserves patience rather than extrapolation.", "regulatory": { "us": "Not approved for any use in dogs. Human formulations are sometimes prescribed off-label, which is legal but places the evidentiary burden entirely on the prescribing veterinarian.", "notes": "Off-label prescribing outside a trial means accepting an unknown risk-benefit ratio in exchange for an unproven benefit." }, "plain_summary": "The most credible candidate for a genuine anti-aging drug in dogs, currently being tested in a real randomized trial that has not yet reported results. There is no honest basis today for giving it to a healthy dog outside that trial.", "what_trials_show": "TRIAD, the Test of Rapamycin in Aging Dogs, is run through the Dog Aging Project and described by its investigators as the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan endpoints performed outside the laboratory in any species. Eligible normally aging dogs at least seven years old receive oral rapamycin or placebo for one year, followed by a two-year observation period. As of 2026, enrollment stands at over 180 dogs against a target of 580, with a handful having completed the full three years. The trial survived a funding crisis via a $7 million grant. The published TRIAD work to date covers cognitive assessment methodology and baseline cohort characteristics rather than any efficacy result. One example: 35 dogs examined for inclusion, with a median age of 9.2 years and median weight of 27.7 kg. Anyone citing rapamycin as proven in dogs is citing mouse data or hope.", "harms": "Not characterized for long-term use in healthy dogs, which is precisely what the trial exists to determine. Rapamycin is an immunosuppressant at transplant doses; the geroscience hypothesis relies on intermittent low doses behaving differently, and that assumption is being tested, not established. Plausible concerns include impaired wound healing, metabolic effects, and infection susceptibility. A healthy dog given this off-label is absorbing unquantified risk for an unquantified benefit.", "practical": { "route": "Oral, intermittent dosing in the trial protocol", "typical_course": "TRIAD protocol: 1 year of dosing, 2 years of observation", "monitoring": "Within the trial, extensive. Outside it, no established monitoring protocol exists.", "cost_signal": "varies" }, "ask_your_vet": [ "Is my dog eligible for TRIAD, and is there an enrolling site near me?", "If you would prescribe this off-label, what monitoring plan and stopping rules would you use, given no protocol has been validated?", "What would we be giving up by waiting for the trial to report?" ], "evidence": [ { "type": "ongoing_trial", "citation": "Dog Aging Project. Test of Rapamycin in Aging Dogs (TRIAD). Multicentre randomized placebo-controlled trial, ongoing.", "year": 2026, "n": 180, "design": "Randomized, placebo-controlled, multicentre", "blinding": "double-blind", "control": "Placebo", "duration": "1 year of treatment plus 2 years of observation", "population": "Healthy, middle-aged, medium-to-large companion dogs aged 7+, target enrollment 580", "primary_outcome": "Lifespan and healthspan", "result": "Enrollment ongoing; no efficacy results published as of mid-2026.", "funding": "National Institute on Aging and philanthropic support, including a $7 million rescue grant", "summary": "The trial that will actually answer this question. Until it reports, the honest answer about rapamycin in dogs is that nobody knows.", "url": "https://dogagingproject.org/triad" }, { "type": "observational", "citation": "Canine cognition assessments in the Test of Rapamycin in Aging Dogs (TRIAD). 2024.", "year": 2024, "n": 35, "design": "Baseline cohort characterization", "blinding": "not-applicable", "population": "Dogs screened for TRIAD inclusion; median age 9.2 years, median weight 27.7 kg", "result": "Median CADES score 1.0, median Sustained Gaze score 9.0 at baseline.", "summary": "Methodological groundwork, explicitly not an efficacy result. Included so the distinction is visible rather than blurred.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11692996/" }, { "type": "regulatory", "citation": "$7M grant rescues dog study investigating rapamycin for canine aging. American Veterinary Medical Association, 2025.", "year": 2025, "design": "News report on trial funding", "blinding": "not-applicable", "result": "Funding secured to continue TRIAD after a shortfall threatened it.", "summary": "Context on why results are slower than the surrounding enthusiasm suggests.", "url": "https://www.avma.org/news/7m-grant-rescues-dog-study-investigating-rapamycin-canine-aging" } ], "see_also": [ "loy-002" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] }, { "id": "glucosamine-chondroitin", "name": "Glucosamine and chondroitin sulfate", "brand_names": [ "Cosequin", "Dasuquin", "and many others" ], "aliases": [ "joint supplements", "chondroprotectants" ], "category": "supplement", "conditions": [ "osteoarthritis" ], "tier": "D", "tier_rationale": "This is not an absence of evidence. It is evidence of absence. A 2022 systematic review and meta-analysis of nutraceuticals in canine and feline osteoarthritis reported a marked non-effect for chondroitin-glucosamine products and explicitly recommended they no longer be recommended for pain management. A randomized trial using objective gait analysis found no significant improvement over placebo while carprofen and meloxicam arms in the same study did improve. Tier D is reserved for interventions where adequately conducted trials found no clinically meaningful benefit.", "regulatory": { "us": "Sold as a supplement, not a drug. Not subject to pre-market efficacy review, and label content frequently fails to match actual content.", "notes": "Because these are supplements, no regulator has ever required them to demonstrate that they work." }, "plain_summary": "The most commonly recommended joint supplement for dogs, and the one with the clearest evidence that it does not meaningfully reduce arthritis pain. Money spent here is better spent on weight loss, omega-3s, or proven pain control.", "what_trials_show": "In a randomized controlled trial using objective kinetic gait analysis, measured variables improved significantly with carprofen and meloxicam but not with a glucosamine-chondroitin product and not with placebo. The supplement performed like placebo in the same study where real drugs separated from it. The 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals found a weak effect for collagen and what the authors described as a very marked non-effect for chondroitin-glucosamine, concluding these products should no longer be recommended for pain management in canine and feline osteoarthritis. Earlier reviews had already characterized the evidence as limited and conflicting despite widespread veterinary recommendation.", "harms": "Very safe, which is genuinely the strongest thing that can be said for it. Occasional gastrointestinal upset. The meaningful harm is opportunity cost and false reassurance: an owner who believes the arthritis is being treated may delay effective pain control, and a dog in untreated chronic pain is the actual cost of this supplement.", "practical": { "route": "Oral", "typical_course": "Commonly given indefinitely, often begun before any diagnosis is confirmed", "monitoring": "If your dog is on this and still slow to rise, that is the signal to reassess rather than to increase the dose", "cost_signal": "moderate" }, "ask_your_vet": [ "Given the 2022 meta-analysis, is there a reason specific to my dog to continue this?", "If we stopped it and redirected the cost to a therapeutic diet or pain control, what would you expect to change?", "Is my dog's pain actually being treated, or only the appearance of doing something about it?" ], "evidence": [ { "type": "meta_analysis", "citation": "Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. International Journal of Molecular Sciences, 2022;23(18):10384.", "year": 2022, "design": "Systematic review and meta-analysis. 1578 publications screened, 57 articles included, comprising 72 trials across nine categories of natural health compound.", "blinding": "not-applicable", "result": "Weak efficacy for collagen and a very marked non-effect for chondroitin-glucosamine nutraceuticals; authors recommended these products no longer be recommended for pain management in canine and feline osteoarthritis.", "funding": "Université de Montréal research groups (GREPAQ and CHUM arthrosis unit); see publication", "summary": "The decisive reference. This is a pooled analysis, not a single disappointing trial.", "url": "https://pubmed.ncbi.nlm.nih.gov/36142319/" }, { "type": "rct", "citation": "Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Veterinary Record, 2003;152(11):323-9.", "year": 2003, "n": 71, "design": "Prospective, randomized, double-blind, placebo-controlled, four-arm", "blinding": "double-blind", "control": "Placebo, plus carprofen and meloxicam as active arms", "duration": "60 days", "population": "71 client-owned dogs over 20 kg with chronic stable osteoarthritis of the elbow, stifle, or hip", "primary_outcome": "Objective ground reaction forces on force-plate gait analysis, plus owner and orthopedic surgeon assessments", "result": "Dogs on meloxicam or carprofen showed significant improvement in ground reaction forces, with meloxicam returning values to normal baseline. The nutraceutical and placebo arms did not improve.", "funding": "See publication", "url": "https://pubmed.ncbi.nlm.nih.gov/12665145/", "summary": "A within-study demonstration that the trial was capable of detecting a real effect. It found one in the NSAID arms and not in the nutraceutical arm." }, { "type": "systematic_review", "citation": "Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: A review. Open Veterinary Journal, 2017;7(1):36-49.", "year": 2017, "design": "Narrative review of the clinical literature", "blinding": "not-applicable", "result": "Concluded the evidence was limited and conflicting despite these being commonly recommended by veterinarians.", "summary": "Documents the long-standing gap between how often these are recommended and what supports them.", "url": "https://pubmed.ncbi.nlm.nih.gov/28331832/" } ], "see_also": [ "omega-3-fatty-acids", "weight-optimization", "nsaids" ], "last_reviewed": "2026-08-04", "contributors": [ "@lextechx" ] } ] }